The broad, long-range objective of these studies is to define the molecular basis of neuronal dysfunction in Alzheimer's disease. We have developed transgenic mice expressing the amyloid precursor protein (APP) for animal studies of Alzheimer's disease (Hsiao et al., 1996). These mice simulate several behavioral and neuropathological features of Alzheimer's disease. We propose to delineate the molecular domains of APP responsible for these behavioral and neuropathological abnormalities. Because hundreds of researchers around the world have begun using these mice as a model for Alzheimer's disease, we feel compelled to dispel even the slightest doubts about the reproducibility of the phenotypic traits we observed. Therefore, we shall embark upon producing another line of mice over-expressing mutant human APP exhibiting both age-related behavioral and pathological abnormalities simulating Alzheimer's disease in humans in AIM #1.
In AIM #2 we shall examine the role of alphabeta in producing age-related neural dysfunction in the brain. By comparing the behavioral and neuropathological profiles of transgenic mice expressing wild-type APP and APP lacking the alphabeta domain to transgenic mice over-expressing mutant APP we shall determine which biological and behavioral abnormalities are due to alphabeta accumulation and which can be attributed solely to APP over-expression. Elucidating the role of alphabeta in functional brain abnormalities in Alzheimer's disease is a critical and timely question that can now be approached by studying neural dysfunction in transgenic APP mice. We shall also distinguish between the more and less amyloidogenic forms of alphabeta, alphabeta40 and alphabeta42(43), by comparing, by comparing behavioral and neuropathological profiles of transgenic mice expressing APP with the Swedish (KM670/671 NL) and London (V717I) mutations.
In Aim #3 we shall determine whether the KPI domain in APP influences the onset and rate of amyloid formation. In different laboratories APP isoforms with or without KPI domains have both been used to generate transgenic mice developing amyloid plaques (Games et al., 1995; Hsiao et al., 1996; Sturchler-Pierrat et al., 1997). Although the topographical and morphological features of the amyloid deposits are remarkably similar in these mice, the presence or absence of the KPI domain in the APP transgene might account for differences in the chronological appearance and amount of alpha/beta deposition. Whether the KPI domain alone can explain these differences remains unresolved because of slight potential variations in APP levels and differences in promoters used to drive APP expression in the two lines of mice. To answer this question we shall compare alphabeta levels, temporal patterns and extent of alphabeta deposits, as well as profiles of behavioral impairment in transgenic mice, expressing mutated APP with and without the KPI domain driven at comparable levels by the identical promoter.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
2R01NS033249-05
Application #
2767235
Study Section
Special Emphasis Panel (ZRG1-BDCN-3 (01))
Program Officer
Heemskerk, Jill E
Project Start
1994-08-01
Project End
2004-01-31
Budget Start
1999-02-15
Budget End
2000-01-31
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Neurology
Type
Schools of Medicine
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Chiang, Angie C A; Fowler, Stephanie W; Reddy, Rohit et al. (2018) Discrete Pools of Oligomeric Amyloid-? Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis. Am J Pathol 188:739-756
Liu, Peng; Reichl, John H; Rao, Eshaan R et al. (2017) Quantitative Comparison of Dense-Core Amyloid Plaque Accumulation in Amyloid-? Protein Precursor Transgenic Mice. J Alzheimers Dis 56:743-761
Sherman, Mathew A; LaCroix, Michael; Amar, Fatou et al. (2016) Soluble Conformers of A? and Tau Alter Selective Proteins Governing Axonal Transport. J Neurosci 36:9647-58
Liu, Peng; Reed, Miranda N; Kotilinek, Linda A et al. (2015) Quaternary Structure Defines a Large Class of Amyloid-? Oligomers Neutralized by Sequestration. Cell Rep 11:1760-71
Weitzner, Daniel S; Engler-Chiurazzi, Elizabeth B; Kotilinek, Linda A et al. (2015) Morris Water Maze Test: Optimization for Mouse Strain and Testing Environment. J Vis Exp :e52706
Liu, Peng; Paulson, Jennifer B; Forster, Colleen L et al. (2015) Characterization of a Novel Mouse Model of Alzheimer's Disease--Amyloid Pathology and Unique ?-Amyloid Oligomer Profile. PLoS One 10:e0126317
Lesne, Sylvain E (2014) Toxic oligomer species of amyloid-? in Alzheimer's disease, a timing issue. Swiss Med Wkly 144:w14021
Qi, Yingjie; Klyubin, Igor; Harney, Sarah C et al. (2014) Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Aß-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: rapid reversal by anti-Aß agents. Acta Neuropathol Commun 2:175
Fowler, Stephanie W; Chiang, Angie C A; Savjani, Ricky R et al. (2014) Genetic modulation of soluble A? rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J Neurosci 34:7871-85
Ashe, Karen H; Aguzzi, Adriano (2013) Prions, prionoids and pathogenic proteins in Alzheimer disease. Prion 7:55-9

Showing the most recent 10 out of 32 publications